Cargando…

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

BACKGROUND: Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoels, Monika M, van der Heijde, Désirée, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murikama, Miho M, Nishimoto, Norihiro, Smolen, Josef S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595140/ https://www.ncbi.nlm.nih.gov/pubmed/23144446 http://dx.doi.org/10.1136/annrheumdis-2012-202470

Ejemplares similares

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
por: Smolen, Josef S, et al.
Publicado: (2013)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Treating rheumatoid arthritis to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2010)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
por: Stoffer, Michaela A, et al.
Publicado: (2016)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
por: Schoels, Monika, et al.
Publicado: (2010)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2016)

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)
por: Gvozdenović, Emilia, et al.
Publicado: (2016)

The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
por: Burmester, Gerd, et al.
Publicado: (2010)

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
por: Buch, Maya H, et al.
Publicado: (2015)

The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases
por: Gabay, Cem, et al.
Publicado: (2009)

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
por: Kastrati, Kastriot, et al.
Publicado: (2022)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
por: van der Heijde, Désirée, et al.
Publicado: (2015)

The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
por: Han, Chenglong, et al.
Publicado: (2007)

Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory Diseases)
por: Gremese, Elisa, et al.
Publicado: (2014)

Introducing RMD Open
por: Cutolo, Maurizio, et al.
Publicado: (2015)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2014)

The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases
por: Al Maini, Mustafa, et al.
Publicado: (2014)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis
por: Mjaavatten, Maria D, et al.
Publicado: (2010)

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
por: Nash, Peter, et al.
Publicado: (2021)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Percentage of progressors in imaging: can we ignore regressors?
por: Sepriano, Alexandre, et al.
Publicado: (2019)

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
por: Hashimoto, Jun, et al.
Publicado: (2010)

An Incorrect Statement
por: Gorgas, Ferdinand J. S.
Publicado: (1889)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases
por: Lamacchia, Celine, et al.
Publicado: (2023)

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
por: Smolen, Josef S, et al.
Publicado: (2016)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Immunomics in inflammatory rheumatic diseases
por: Konthur, Z, et al.
Publicado: (2004)

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ri61ubtu4orh8fh6442l6kacka